Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
Daiichi Sankyo’s FLT3 inhibitor quizartinib demonstrated a reduction of 22.4% in the risk of deaths versus chemotherapy alone when used for the first-line treatment of FLT3-ITD positive acute myeloid leukemia (AML), the latest PIII data show. The Japanese drug maker…
To read the full story
Related Article
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
April 24, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
August 24, 2022
- Quizartinib Shows OS Benefit in Frontline AML, Daiichi Sankyo Mulls US/EU Filing
November 22, 2021
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
- Daiichi Sankyo’s Quizartinib Voted Down by US FDA Advisory Committee
May 16, 2019
- FDA Extends Quizartinib Review by 3 Months: Daiichi Sankyo
April 5, 2019
- Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Earns FDA’s Priority Review Status
November 26, 2018
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…